A better understanding of high-cost kidney transplant patients would be useful for informing value-based purchasing strategies by payers. This retrospective cohort study was based on the Medicare Provider Analysis and Review (MEDPAR) files from 2003 to 2006. The focus of this analysis was high-cost kidney transplant patients (patients that qualified for Medicare outlier payments and 30-day readmission payments). Using regression techniques, we explored relationships between high-cost kidney transplant patients, center-specific case mix, and center quality. Among 43 393 kidney transplants in Medicare recipients, 35.2% were categorized as high-cost patients. These payments represented 20% of total Medicare payments for kidney transplantation and exceeded $200 million over the study period. Case mix was associated with these payments and was an important factor underlying variation in hospital payments high-cost patients. Hospital quality was also a strong determinant of future Medicare payments for high-cost patients. Compared to high-quality centers, low-quality centers cost Medicare an additional $1185 per kidney transplant. Payments for high-cost patients represent a significant proportion of the total costs of kidney transplant surgical care. Quality improvement may be an important strategy for reducing the costs of kidney transplantation.
Introduction
Kidney transplantation is expensive. The costs of an uncomplicated renal transplant event are approximately $100 000 for the first in 90 days of care (1, 2) . CMS is the primary payer for most of kidney transplant patients and though kidney transplantation is cost effective compared to long-term dialysis, kidney transplant recipients consume significant healthcare resources (3) . CMS spends $27 billion/year on the care of renal failure patients, and approximately 13% of this amount is for kidney transplantation (4) .
Reducing adverse outcomes following kidney transplantation may be one strategy for reducing these high costs. Clearly, payments associated with adverse surgical outcomes represent a significant expense for CMS (5, 6) . For example, postkidney transplant sepsis the costs insurers $48 000, posttransplant pneumonia costs insurers $38 000 and postkidney transplant urinary complications are associated with $28 000 of additional insurer costs (1, 2, 7) . Significant variation among hospitals in outcomes suggests opportunities to avoid excess costs associated with adverse outcomes and high-cost patients (8, 9) . 
In this context, we studied Medicare payments associated with high-cost patients

Within this context, the goals of this article include: (i) Describe the epidemiology of Medicare payments for high-cost patients in kidney transplantation. (ii) Describe the relationship between these all payments
and both measures of high-risk patients and poor quality. 
Methods
Subjects and data bases
Variation in payments across hospitals Among kidney hospitals, there was significant variation in the average proportion of total Medicare payments attributable to high-cost patients (Figure 1). The proportion of patients qualifying for payments for high-cost patients ranged across hospitals, from 5% to 50%.
We then assessed the relationship between hospital case mix and payments for high-cost patients. Hospital case mix was stratified by terciles (ranging from high risk to low risk) and then related to the proportion of cases that qualified for payments for high-cost patients (Figure 2). Hospitals with the highest risk case mix had the highest proportion of cases that qualified as high-cost patients. Similarly, hospital case mix was stratified by terciles and then related to the proportion of hospital reimbursement from payments for high-cost patients (Figure 3). Hospitals with the highest risk case mix had the highest proportion of hospital reimbursement from payments for high-cost patients.
Kidney Transplant Costs (20) (21) (22) 
We then assessed the relationship between historical hospital performance (hospital quality 2003-2004) and future payments for high-cost patients (2005-2006). Hospital performance was stratified by terciles (ranging from low quality to high quality) and then related to the proportion of cases that qualified for payments for high-cost patients (Figure 2). Similar to the hospitals with the highest risk case mix, hospitals of the lowest historical performance had the highest future proportion of cases that qualified for payments for high-cost patients. Then, hospital quality was stratified by terciles and related to the proportion of hospital reimbursement from payments for high-cost patients (Figure 3
)
There is little previous work in transplantation focusing on the relationship between quality and costs. Clearly, postoperative complications have been linked to increased hospital costs (16-19). Similarly, variations in case mix such as donor quality or recipient burden of illness have been associated with hospital costs
